TY - JOUR
T1 - Capecitabine, oxaliplatin and radiotherapy
T2 - A phase IB neoadjuvant study for esophageal cancer with gene expression analysis
AU - Javle, Milind M.
AU - Yang, Gary
AU - Nwogu, Chumy E.
AU - Wilding, Gregory E.
AU - O'Malley, Linda
AU - Vinjamaram, Sanjay
AU - Schiff, Michael D.
AU - Nava, Hector R.
AU - LeVea, Charles
AU - Clark, Kimberly R.
AU - Prey, Joshua D.
AU - Smith, Patrick F.
AU - Pendyala, Lakshmi
N1 - Funding Information:
Keywords: Esophageal neoplasms, Neoadjuvant therapy, Capecitabine, Oxaliplatin, Gene expression. This study was supported by Roche Pharmaceuticals. Presented in part at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, San Francisco, CA; January 26, 2006 Correspondence to: Milind Javle, MD Department of Gastrointestinal Medical Oncology Unit 426, The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd. Houston, TX 77030-4009 USA tel: (713) 745-8832 fax: (713) 563-0543 email: [email protected]
PY - 2009/2
Y1 - 2009/2
N2 - Purpose: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer. Patients and Methods: Oxaliplatin (85 mg/m2) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m2 with 50.4 Gy radiation. Results: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p ≤ 0.05). Conclusion: The maximal tolerated dose was 85 mg/m2 of oxaliplatin, 1,250 mg/m2/day of capecitabine, and 50.4 Gy of radiation. Copyright © Informa Healthcare USA, Inc.
AB - Purpose: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer. Patients and Methods: Oxaliplatin (85 mg/m2) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m2 with 50.4 Gy radiation. Results: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p ≤ 0.05). Conclusion: The maximal tolerated dose was 85 mg/m2 of oxaliplatin, 1,250 mg/m2/day of capecitabine, and 50.4 Gy of radiation. Copyright © Informa Healthcare USA, Inc.
KW - Capecitabine
KW - Esophageal neoplasms
KW - Gene expression
KW - Neoadjuvant therapy
KW - Oxaliplatin
KW - Esophageal Neoplasms/metabolism
KW - Humans
KW - Middle Aged
KW - Cytidine Deaminase/genetics
KW - Male
KW - Thymidine Phosphorylase/genetics
KW - Carboxylesterase/genetics
KW - Combined Modality Therapy
KW - Deoxycytidine/administration & dosage
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Organoplatinum Compounds/administration & dosage
KW - Fluorouracil/administration & dosage
KW - Adult
KW - Female
KW - Aged
UR - https://www.scopus.com/pages/publications/60849110846
UR - https://www.scopus.com/pages/publications/60849110846#tab=citedBy
UR - https://www.mendeley.com/catalogue/c780c9e1-b4ba-3db2-8122-bc4e4f0c7344/
U2 - 10.1080/07357900802172093
DO - 10.1080/07357900802172093
M3 - Article
C2 - 19235592
SN - 0735-7907
VL - 27
SP - 193
EP - 200
JO - Cancer Investigation
JF - Cancer Investigation
IS - 2
ER -